1. Home
  2. RAIL vs HURA Comparison

RAIL vs HURA Comparison

Compare RAIL & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FreightCar America Inc.

RAIL

FreightCar America Inc.

HOLD

Current Price

$7.69

Market Cap

149.9M

Sector

Industrials

ML Signal

HOLD

Logo TuHURA Biosciences Inc.

HURA

TuHURA Biosciences Inc.

HOLD

Current Price

$2.28

Market Cap

144.3M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAIL
HURA
Founded
1901
2009
Country
United States
United States
Employees
N/A
22
Industry
Railroads
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
149.9M
144.3M
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
RAIL
HURA
Price
$7.69
$2.28
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$9.50
AVG Volume (30 Days)
136.4K
557.8K
Earning Date
05-04-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
134.94
N/A
EPS
1.15
N/A
Revenue
$500,991,000.00
N/A
Revenue This Year
$6.54
N/A
Revenue Next Year
$30.90
N/A
P/E Ratio
$6.77
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.27
$0.41
52 Week High
$14.90
$3.90

Technical Indicators

Market Signals
Indicator
RAIL
HURA
Relative Strength Index (RSI) 39.90 46.45
Support Level $7.58 $2.24
Resistance Level $10.18 $2.68
Average True Range (ATR) 0.31 0.22
MACD 0.02 -0.03
Stochastic Oscillator 14.29 9.48

Price Performance

Historical Comparison
RAIL
HURA

About RAIL FreightCar America Inc.

FreightCar America Inc is a diversified manufacturer and supplier of railcars and railcar components. It designs and manufactures a variety of railcar types for transportation of bulk commodities and containerized freight products in North America. The company also provides railcar rebody and repair services, railcar conversion services, and supplies railcar parts. The company has two segments: Manufacturing and Aftermarket. The majority of the company's revenue is derived from the Manufacturing segment, which includes new railcar manufacturing, used railcar sales, and various conversions and rebodies. Geographically, it generates the maximum revenue from the United States.

About HURA TuHURA Biosciences Inc.

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

Share on Social Networks: